Figure 6 shows the effects of SGLT2 inhibitors on serum adiponectin levels and our analysis demonstrated no significant effect (SMD = −0.04; 95% CI: −0.37, 0.29, p = 0.80; Figure 6). Subgroup analyses revealed a significant adiponectin-improving effect in placebo-controlled studies (SMD: 0.28; 95% CI: 0.15, 0.41, p < 0.001) with no heterogeneity, but it was not significantly reduced in diabetes medications-controlled studies (SMD: −0.51; 95% CI: −1.30, 0.27, p = 0.20). The gene discussed is SLC5A2; the disease is diabetes mellitus.